The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Competition in ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug Zepbound, can now meet present and projected national demand, the FDA said in a statement.

An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet ...

Losing weight these days may be that much easier, thanks to a new crop of drugs that are helping people take off the pounds. An Eli Lilly and Company drug in development that's showing positive ...

This image provided by Eli Lilly on Wednesday, Nov. 8, 2023 shows packaging for their new drug Zepbound. The new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss ...

FDA approves weight loss drug from Eli Lilly that helped people lose up to 52 pounds. Some analysts predict the weekly injectable medication could become the best-selling drug of all time.

FDA approves weight loss drug Zepbound, joining Ozempic and Wegovy in market 04:47. Eli Lilly has a message for people who are taking prescription medications developed for patients with Type 2 ...

Eli Lilly just debuted its powerful new weight-loss drug, Zepbound. Zepbound is about 20% cheaper than competing drug Wegovy, which may help some Americans save money. Still, at over $1,000 a ...

Eli Lilly and rival Novo Nordisk have been battling the emerging industry making copies of their top-selling diabetes and weight-loss drugs, a situation without modern precedent.